- Characteristics of familial pancreatic cancer families with additional colorectal carcinoma.
- Lehman B, Matthäi E, Gercke N, Denzer UW, Figiel J, Hess T, Slater EP, Bartsch DK.
- Fam Cancer. 2023 Jan 31. doi: 10.1007/s10689-023-00328-1. Epub ahead of print.
- PMID: 36717525
- PubMed abstract
- The Use of Instagram by Gynecologic Oncology Providers as a Patient Education Tool for Patients at High-Risk of Gynecologic Cancer.
- Holtzman S, Carr C, Zeligs K, Blank SV.
- Gynecol Oncol Rep. 2023 Jan 31;101143. doi: 10.1016/j.gore.2023.101143.
- Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
- Terra L, Lee Meeuw Kjoe PR, Agelink Van Rentergem JA, Beekman MJ, Heemskerk-Gerritsen BAM, Van Beurden M, Roeters Van Lennep JE, Van Doorn HC, De Hullu JA, Mourits MJE, Van Dorst EBL, Mom CH, Slangen BFM, Gaarenstroom KN, van der Kolk LE, Collée JM, Wevers MR, Ausems MGEM, Van Engelen K, Van De Beek I, Berger LPV, Van Asperen CJ, Gomez Garcia EB, Maas AHEM, Hooning MJ, Van Der Wall E, Van Leeuwen FE, Schagen SB.
- BJOG. 2023 Jan 30. doi: 10.1111/1471-0528.17415. Epub ahead of print.
- PMID: 36715559
- PubMed abstract
- Source abstract
- Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.
- Han S, Camp SY, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker CA, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri TK, AlDubayan SH, Van Allen EM.
- medRxiv [Preprint]. 2023 Jan 19:2023.01.18.23284664. doi: 10.1101/2023.01.18.23284664.
- PMID: 36712083
- PubMed abstract
- Source abstract
- Preprint
- Free PMC article
- Free Full Text (PDF)
- Estimating clinical risk in gene regions from population sequencing cohort data.
- Fife JD, Cassa CA.
- medRxiv [Preprint]. 2023 Jan 9:2023.01.06.23284281. doi: 10.1101/2023.01.06.23284281.
- PMID: 36711752
- PubMed abstract
- Source abstract
- Preprint
- Free PMC article
- Free Full Text (PDF)
- Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
- Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I.
- JCO Precis Oncol. 2023 Jan;7:e2200258. doi: 10.1200/PO.22.00258.
- PMID: 36716415
- PubMed abstract
•• Identifier: NCT02477644: Platine, Avastin and OLAparib in 1st Line (PAOLA-1). (ClinicalTrials.gov . Accessed 2023 Jan 30.)